Department of Medicine
Faculty Profiles by Division

Division of Pulmonary, Allergy and Critical Care Medicine

Faculty Profiles

[Return To Index page]
photo Kevin F. Gibson, MD

Pulmonary, Allergy and Critical Care Medicine

Professor of Medicine, Clinical and Translational Science

Medical Director, Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease


Phone: 412-624-7225

Office: UPMC Montefiore Hospital, NW628
3459 Fifth Avenue
Pittsburgh, PA 15213
Phone: 412-624-7225
Fax: 412-624-1670
Administrative Assistant:
Stacie Truszkowski
Phone: 412-624-7225
Fax: 412-624-1670
Education and Training
BA, Drew University, 1976
MD, UMDNJ - Rutgers Medical School, 1980
Internship, Internal Medicine, Emory University, 1981
Residency, Internal Medicine, Emory University, 1983
Fellowship, Pulmonary and Critical Care, University of Pittsburgh School of Medicine, 1987
Research Fellowship, University of Pittsburgh, 1987
Research Interest
Dr. Gibson’s research focuses on clinical pathogenesis interstitial lung diseases including idiopathic pulmonary fibrosis, Sarcoidosis, autoimmune lung disease, and Occupational lung disease. Dr. Gibson conducts studies that include early and late phase clinical trials of novel therapeutics in interstitial lung disease, the discovery of biomarkers of disease activity and progression, and clinical translational studies of disease pathogenesis. He has published a number of translational studies to identify unique biomarkers of disease activity in idiopathic pulmonary fibrosis and other interstitial lung diseases, studies of novel interventions in acute IPF exacerbations, as well as studies of gene expression profiling in IPF lungs. He has discovered a number of peripheral blood biomarkers that have been useful predicting disease progression in idiopathic pulmonary fibrosis. He has participated in multinational Studies of the genetics of IPF and Sarcoidosis.
Clinical Interest
Dr. Gibson is the medical director of the Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease. He is in charge of all clinical research in the center and has an active consultative practice focusing on all of the diffuse parenchymal lung diseases including the idiopathic interstitial pneumonias, autoimmune lung diseases, hypersensitivity pneumonitis, genetic-based interstitial lung diseases, and Sarcoidosis. He is principal investigator on a large number of government-sponsored and industry-funded clinical trials of novel therapeutic agents and therapeutic approaches to disease such as idiopathic pulmonary fibrosis, Sarcoidosis, and pulmonary fibrosis from secondary causes.
Educational Interest
Dr. Gibson's educational activities in the school of medicine have focused on the idiopathic interstitial pneumonias, occupational lung diseases, and Sarcoidosis.
For my complete bibliography, Click Here.
Selected Publications:
Huang, Y, Ma, SF, Vij, R, Oldham, J, Herazo-Maya, J, Broderick, S, Strek, ME, White, SR, Hogarth, DK, Sandbo, NK, Lussier, YA, Kaminski, N, Garcia, JGN, North, I, Gibson, KF. A functional genomic model for predicting prognosis in idiopathic pulmonary fibrosis. BMC Pulmonary Medicine. 2015; Nov 21;15: 147.
Raghu, G, Martinez, FJ, Brown, KK, Costabel, U, Cottin, V, Wells, AU, Lancaster, L, Gibson, KF, Haddad, T, Agarwal, P, Mack, M, Dasgupta, B, Nnane, IP, Flavin, SK, Barnathan, ES. CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab. Eur Respir J. 2015; Oct 22.
Moller, DR, Koth, LL, Maier, LA, Morris, A, Drake, W, Rossman, M, Leader, JK, Collman, RG, Hamzeh, N, Sweiss, NJ, Zhang, Y, O'Neal, S, Senior, RM, Becich, M, Hochheiser, HS, Kaminski, N, Wisniewski, SR, Gibson, KF. GRADS Sarcoidosis Study Group. Rationale and Design of the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis Study (GRADS): Sarcoidosis Protocol. Ann Am Thorac Soc. 2015; Oct;12(10): 1561-71.
Donahoe, M, Valentine, VG, Chien, N, Gibson, KF, Raval, JS, Saul, M, Xue, J, Zhang, Y, Duncan, SR. Autoantibody-Targeted Treatments for Acute Exacerbations of Idiopathic Pulmonary Fibrosis. PLoS One. 2015; Jun 17;10(6): e0127771.
Han, S, Lear, TB, Jerome, JA, Rajbhandari, S, Snavely, CA, Gulick, DL, Gibson, KF, Zou, C, Chen, BB, Mallampalli, RK. Lipopolysaccharide primes the NALP3 inflammasome by inhibiting its ubiquitination and degradation mediated by the SCFFBXL2 E3 ligase. J Biol Chem. 2015; Jun 2 (Epub ahead of print).
Bauer, Y, Tedrow, J, de Bernard, S, Birker-Robaczewska, M, Gibson, KF, Juan Guardela, B, Hess, P, Klenk, A, Lindell, KO, Poirey, S, Renault, B, Rey, M, Weber, E, Nayler, O, Kaminski, N. A Novel Genomic Signature with Translational Significance for Human Idiopathic Pulmonary Fibrosis. Am J Respir Cell Mol Biol. 2015; Feb;52(2): 217-31.
Schneider, F, Aggarwal, R, Bi, D, Gibson, K, Oddis, C, Yousem, SA. The Pulmonary Histopathology of Anti-KS Transfer RNA Synthetase Syndrome. Arch Pathol Lab Med. 2015; Jan;139(1): 122-5.
Wilkes, DS, Chew, T, Flaherty, KR, Frye, S, Gibson, KF, Kaminski, N, Klemsz, MJ, Lange, W, Noth, I, Rothhaar, K. Oral immunotherapy with type V collagen in idiopathic pulmonary fibrosis. Eur Respir J. 2015; Jan 22.
Peljto, AL, Zhang, Y, Fingerlin, TE, Ma, SF, Garcia, J, Richards, TJ, Silveiri, LJ, Lindell, KO, Steele, MP, Loyd, JE, Gibson, KF, Seibold, MA, Brown, KK, Talbert, JL, Markin, C, Kossen, K, Seiwert, SD, Murphy, E, Noth, I, all. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA. 2013; June 5;309(21): 2232-9.
Fingerlin, TE, Murphy, E, Zhang, W, Peljto, AL, Brown, KK, Steele, MP, Loyd, JE, Cosgrove, GP, Lynch, D, Groshong, S, Collard, HR, Wolters, PJ, Bradford, WZ, Kossen, K, Seiwert, SD, du Bois, RM, Garcia, CK, Devine, MS, Gibson, KF, all. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet. 2013; Jun;45(6): 613-20.
Sponsored Research/Activities
Title: LTRC Clinical Center (Characterization)
Role: Co-Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Start Year: 2016
End Year: 2019
Title: Network Management Core (NEMO) for the Pulmonary Trials Cooperative (PTC)
Role: Co-Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: U01 HL128954
Start Year: 2015
End Year: 2020
Title: A PaTH Toward a Learning Health System for the Mid-Atlantic Region
Role: Co-Investigator
Funding Agency: Patient-Centered Outcomes Research Institute
Start Year: 2015
End Year: 2018
Title: Rituximab Therapy in Patients with IPF
Role: Co-Investigator
Funding Agency: University of Alabama at Birmingham/National Heart, Lung, & Blood Institute
Grant Number: R01 HL119960
Start Year: 2014
End Year: 2018
Title: RV/PA Recoupling by Bone Marrow Derived Mesenchymal Stem Cells
Role: Co-Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: R01 HL114795
Start Year: 2012
End Year: 2017
Notable Achievements
Best Doctors in America, 2007-2016
Pittsburgh Courier's "50 Men of Excellence", 2011
University of Pittsburgh Innovator Award, 2012